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Objective: To examine if the beneﬁcial effect of statin
medication on mortality seen in randomised clinical
trials of type 2 diabetes applies equally to
observational studies in the general population of older
people.
Design: A prospective, population-based cohort study.
Setting: Reykjavik, Iceland.
Participants: 5152 men and women from the Age,
Gene/Environment Susceptibility-Reykjavik Study,
mean age 77 years, range of 66e96 years.
Main outcome measure: Cardiovascular and all-
cause mortalities and the RR of dying according to
statin use and history of coronary heart disease (CHD)
in persons with type 2 diabetes and those without
diabetes with a median follow-up time of 5.3 years,
until end of 2009.
Results: The prevalence of type 2 diabetes was 12.4%
of which 35% used statins. Statin use was associated
with a 50% (95% CI 8% to 72%) lower cardiovascular
mortality and 53% (29% to 68%) lower all-cause
mortalities in persons with diabetes. For those without
diabetes, statin use was associated with a 16% ( 24%
to 43%) lower cardiovascular and 30% (11% to 46%)
lower all-cause mortalities. Persons with diabetes
using statins had a comparable risk of cardiovascular
and all-cause mortality to that of the general
population without diabetes. The effect was
independent of the level of glycaemic control.
Conclusion: This observational study lends important
support to existing data from randomised clinical
trials. These data suggest that in the general
population of older people with diabetes, statin
medication markedly reduces the excess
cardiovascular and all-cause mortality risk, irrespective
of the presence or absence of coronary heart disease
or glucose-lowering medication.
INTRODUCTION
The excess risk of vascular disease in persons
with diabetes is about twofold compared
with those without diabetes and is indepen-
dent of other conventional cardiovascular
risk factors. This was clearly demonstrated in
the meta-analysis from 102 prospective
studies, recently published by the Emerging
Risk Factors Collaboration.
1 The beneﬁcial
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- Clinical trials have shown that statin medication
is beneﬁcial for persons with diabetes as
regards cardiovascular morbidity and mortality.
- This is not well established, except within the
rigours of randomised clinical studies.
Key messages
- This population-based observational study of
older individuals demonstrates that treatment
with statins in persons with diabetes reduces
cardiovascular mortality to a level comparable
with that observed in those without diabetes.
- The effect observed is of a magnitude compa-
rable with that reported in randomised clinical
trials.
Strengths and limitations of this study
- A major strength of the study is the proportion-
ally large national representation in this popu-
lation-based cohort, the high participation rate
and the comprehensive information on
morbidity and mortality. The effect observed is
of comparable magnitude to the effect reported
in randomised clinical trials.
- A limitation is the non-attendance of frail
individuals in the study that may cause a possible
bias towards more healthy individuals at baseline
of this study.
Non-attendees in the study have been shown,
however, at earlier visits to have comparable
levels of conventional cardiovascular risk factors.
A limitation is the unavailability of dietary
information for
this analysis. A weakness in our study is
the relatively low number of events during the 5-
year follow-up. A limitation is the lack of glucose
tolerance test for diagnosis of diabetes.
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Open Access Researcheffects of statins in reducing major vascular events in
patients with diabetes, irrespective of their baseline lipid
levels, have been demonstrated in a number of rando-
mised clinical trials.
2e5 Additionally, improved life
expectancy in recent years of persons with type 2 dia-
betes, relative to those without diabetes, has been
reported,
6e8 although a difference still exists. This
improvement is possibly a result of better adherence to
published clinical guidelines, advocating aggressive
multifactorial treatment.
9 However, many patients with
type 2 diabetes are still not receiving treatment with
statin medication.
10 11
Although randomised clinical trials have clearly
demonstrated the beneﬁt of statin use with regard to
cardiovascular morbidity and mortality, every physician
will daily face the question of whether these trial results
apply to their patient. A general population of individ-
uals, with a varied background of comorbidities which
may or may not have excluded them from participation,
is not fully represented in the aforementioned trials.
This is why it is of key importance to gather conﬁrmatory
information from population-based observational
studies. One recent prospective population-based
study
10 from the UK General Practice Database has
indeed reported the beneﬁcial effect of statin treatment
in lowering all-cause mortality in type 2 diabetes. Older
persons are under-represented in clinical trial data, and
it is therefore particularly important to obtain informa-
tion on the potential improvement in life expectancy
with statin use in older persons with type 2 diabetes, as
well as data on the relative impact of lipid-lowering
treatment in that age group. This will help in clarifying
at a population-based level whether current guidelines
should be applied to older persons, who may have had
diabetes for an extended period of time.
The present study addresses this information gap by
exploring treatment modalities and cardiovascular and
total mortality in older individuals with diabetes in the




Between 2002 and 2006, the AGES-Reykjavik Study re-
examined 5764 unselected survivors of the original
cohort who had previously participated in the Reykjavik
Study.
12 In the present study, 5152 of these survivors are
included, with a mean age of 77 years (range 66e96)
and a median follow-up time of 5.3 years until the end of
2009. Informed consent was obtained from all study
participants. The Reykjavik Study cohort originally
comprised a random sample of 30795 men and women
born in 1907e1935, living in Reykjavik in 1967 that were
invited to participate in a long-term prospective cardio-
vascular survey. A total of 19381 attended, resulting in
a 71% recruitment rate.
12
A sp a r to ft h eb a s e l i n ee x a m i n a t i o ni nt h eA G E S -
Reykjavik Study, a comprehensive questionnaire was
administered. In order to eliminate any persons with
type 1 diabetes in the study, participants reporting
o n s e to fd i a b e t e sb e f o r et h ea g eo f4 0w e r en o t
included; neither were participants not completing
their questionnaire or having incomplete data for
other study variables included: 66 had missing data
about diabetes history on questionnaire; 21 were
considered to have diabetes of type 1; 78 had missing
data on risk factors (cholesterol, systolic blood pres-
sure, body mass index, triglycerides); 447 had missing
haemoglobin A1c (HbA1c). Participants were asked to
bring all medications and supplements used in the
previous 2 weeks to the clinic. All participants also had
af a s t i n gb l o o ds p e c i m e nd r a w na n da n a l y s e da sd o c u -
mented below.
The criteria used for type 2 diabetes diagnosis were
a fasting serum glucose of $7 mmol/l at the visit to the
clinic, based on the WHO recommendations from
1999,
13 self-reported diabetes in the questionnaire and/
or use of diabetes medication.
Blood samples were drawn after overnight fasting.
Total cholesterol, high-density lipoprotein (HDL)
cholesterol, triglycerides, high-sensitivity C-reactive
protein (CRP), glucose and HbA1c were analysed on
a Hitachi 912, using reagents from Roche Diagnostics
and following the manufacturer’s instructions. Low-
density lipoprotein (LDL) was calculated using the
Friedewald equation.
14
Blood pressure was measured with a mercury sphyg-
momanometer with a large cuff, and the mean value of
two consecutive blood pressure measurements was used
in the analysis. Height and weight were measured, and
BMI was calculated as kg/m
2.
Participants answered questions about frequency of
moderate or vigorous physical activity, both current and
in midlife. Answers were categorised into never, rarely,
occasionally, moderate or high frequency of participa-
tion. In this study, a binary variable for physical activity
was used as an indicator for occasional or a higher
frequency of participation versus never or rarely
participating.
Answers about education were categorised into
a binary variable: higher than secondary education
versus secondary education or less.
Information on the causes of death was based on data
from a complete adjudicated registry of deaths available
from the Icelandic National Roster (http://www.statice.is/
Statistics/Population/Births-and-deaths). All-cause mortality
was deﬁned according to ICD 9-10. In this study, we
calculated an individual’s time at risk from the date of
participation in the baseline survey until the date of
death from cardiovascular disease (ICD-9 and ICD-10:
deﬁned as in the SCORE project
15) or from all causes, or
until the end of follow-up in the cohort. The informa-
tion is collected from National Health System Records by
the Icelandic Heart Association.
The study was approved by the National Bioethics
Committee in Iceland (VSN 00-063) as well as the
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S t a t i n sa n dm o r t a l i t yi nT 2 DInstitutional Review Board of the Intramural Research
Program of the National Institute on Ageing and the
Data Protection Authority in Iceland.
Statistical analyses
Baseline characteristics of participants by sex and diabetic
status in the AGES-Reykjavik Study were compared using
either linear or logistic regression with age adjustment.
Skewed variables were log-transformed. The Cox propor-
tional hazards regression model was used to estimate
mortalities and HRs for the effect of risk factors and statin
use. Time since entering the study was used as the time-
scale. For HR estimates, an adjustment was made for age
and sex in a simple model, and additionally for the
following cardiovascular risk factors: cholesterol, HDL
cholesterol, systolic blood pressure, BMI, triglycerides,
CRP, hypertensive medication and current smoking. An
additional analysis of mortalities was done with adjustment
for physical activity and education level. A separate term
was used in the survival models to represent subgroups,
formed by diabetes, history of CHD and statin use. The
mortality was estimated from the average of the cumulative
hazard function after a ﬁve-year follow-up and represented
as the rate per 1000 person-years. The proportionality
assumption for the HR associated with type 2 diabetes was
inspected graphically and by testing the signiﬁcance of the
interaction of type 2 diabetes statuses with the logarithm of
the follow-up of time analysed as a time-dependent cova-
riate. Signiﬁcance testing was two-sided and based on a 5%
probability level. We analysed the data using SAS/STAT
software, version 9.2.
RESULTS
The mean age of the 5152 AGES-Reykjavik Study partici-
pants was 77.0 (65.8) years, with an age range of
66e96 years. The baseline characteristics in men and
women with and without type 2 diabetes according to
statin use are shown in table 1. A higher percentage of
individuals with type 2 diabetes were hypertensive than
those without diabetes; they also had lower HDL choles-
terol but higher triglycerides and BMI, irrespective of
statin use. Statin medication reduced the mean level of
total and LDL cholesterol similarly in those with and
without diabetes, or by about 1.2 mmol/l in both men
andwomen.Instatinusers,CRPwaslowerby0.30 mg/lin
men and 0.50 mg/l in women without diabetes and 0.80
and 1.05 mg/l respectively in those with diabetes. The
prevalence of coronary heart disease estimated from
hospital records in persons without diabetes using statins
was 71.1% in men and 34.4% in women compared with
7.9% and 2.2% respectively in those not using statins. In
individuals with diabetes, the coronary heart disease
prevalence was 59.4% in men and 24.2% in women using
statins, compared with 14.8% and 8.6% respectively in
those not on statins. Over 93% of all statin users were
hypertensive, compared with 78% of non-statin users.
The prevalence of type 2 diabetes and use of glucose-
lowering treatment in men and women is shown in table
2. About 16% of men and 9.5% of women in the cohort
had type 2 diabetes, and the proportion of persons with
diabetes undiagnosed at baseline was 31%. In the group
with previously diagnosed type 2 diabetes, 23% of the
men and 35% of the women controlled their blood sugar
level with diet only. As shown in table 2, less than 7% of
persons with diagnosed diabetes were simultaneously
taking three or four drugs for lowering blood glucose.
For participants with a prior diagnosis of diabetes, the
average time from diagnosis at baseline assessment was
just over 10 years.
Effect of statins on cardiovascular and all-cause mortality
The 5-year average cardiovascular disease mortality and
all-cause mortalities for those with and without diabetes
are shown in ﬁgure 1. Mortality is estimated according to
statin use and prevalence of coronary heart disease,
adjusted to age 75, sex and the mean levels of cardio-
vascular risk factors (cholesterol, HDL cholesterol,
systolic blood pressure, BMI, triglycerides, hypertensive
medication and current smoking) within each cohort.
About 26% of men and 16% of women without diabetes
and about 35% in both sexes with diabetes were statin
users. Statin medication was administered to 69.2% of
persons with prevalent coronary heart disease and
known diabetes compared with 31.6% of those with
known diabetes but without coronary heart disease
(supplementary table 1).
For individuals with diabetes and prevalent coronary
heart disease, statin use was associated with a signiﬁcantly
lower rate of cardiovascular disease mortality (ﬁgure 1A)
compared with those not using statins, or 11.3 vs 24.6 per
1000 person years. This amounts to a 54% (95% CI 14%
to 75%) lower mortality in statin users. Similarly, statin
use was associated with an all-cause mortality of 27.8 vs
63.3 per 1000 person years when comparing the same two
groups (ﬁgure 1B), amounting to 55% (31% to 71%)
lower mortality in statin users. In individuals with dia-
betes but without coronary heart disease, the rate was
48% (1% to 73%) lower for cardiovascular disease
mortality and 52% (26% to 69%) lower for all-cause
mortality in the group using statins compared with non-
statin users. Combining the groups, the hazard of
cardiovascular disease mortality was 50% lower in statin
users compared with non-statin users, and the all-cause
mortality was 53% lower (supplementary table 2).
Statin use was associated with 16% ( 24% to 43%)
lower cardiovascular mortality in individuals without
diabetes, as shown in ﬁgure 1, albeit not statistically
signiﬁcant. For all-cause mortality, statin users had a 30%
(11% to 46%) lower mortality than non-statin users.
The effect of statins was not modiﬁed by the level of
HbA1c, the use of oral hypoglycaemic or hypertensive
medication, or whether the diabetes was prevalent or
newly diagnosed (supplementary ﬁgures 1, 2).
An additional analysis of mortalities with adjustment
for current physical activity and education level did not
have any material effect on the results or the conclusions
drawn from the data. The additionally adjusted mortal-
ities are shown in supplementary ﬁgure 3.
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S t a t i n sa n dm o r t a l i t yi nT 2 DThe dramatic effect of statin medication use on
mortality in persons with diabetes is also reﬂected in the
HRs for the RR of cardiovascular and all-cause mortality
in individuals with diabetes compared with those
without, as shown in table 3. In persons with diabetes
and prevalent coronary heart disease not on statins, the
RR of dying from cardiovascular disease was 3.33
(2.05e5.50) when compared with those without dia-
betes, after adjusting for age, sex and cardiovascular risk
factors. The individuals treated with statins, however,
had an RR of 1.51 (0.83e2.75). In persons with diabetes
but without coronary heart disease not on statins, the RR
was 1.40 (1.03e1.89) compared with 0.71 (0.31e1.62)
for those on statins. Adding CRP to the risk factor
adjustment showed minimal attenuation of the HRs
(table 3). This implies that the protective effect of statins
is not solely attributable to the effect on these cardio-
vascular risk factors.
DISCUSSION
The major ﬁnding in our population-based AGES-
Reykjavik Study of older individuals with diabetes is the
marked improvement in survival associated with statin
medication when compared with those not receiving
statins, with respect to cardiovascular and all-cause
mortality. This is independent of prevalent coronary
heart disease or glucose-lowering treatment, reducing
the mortality in individuals with diabetes to a level
comparable with those without diabetes.
Statin medication in diabetes has increased gradually
during the last decade. Data from the UK General
Practice Research Database showed an increase in statin
use from about 5% in 1996 to 63.5% in women and
71.0% in men in 2005,
10 which was associated with HRs
of mortality of 0.29 in women and 0.34 in men in the
ﬁrst 2 years following diagnosis of diabetes. Similarly, in
Denmark, only 7% of patients receiving glucose-lowering
medication also received statins in 1997, but this had
increased to 62% in 2007
11; information on mortality in
that study is however lacking. In our cohort of older
persons with diabetes, the prevalence of statin medica-
tion use was 35% overall. In those with known diabetes
but without coronary heart disease, the prevalence of
statin medication use was 31.6%, but 11.6% in those
newly diagnosed without coronary heart disease. One
may speculate if this low prevalence of statin use is due to
Icelandic physicians’ unawareness of results from recent
clinical trials or simply their belief that the evidence does
not apply to older patients in general.
It is of course well recognised that statin treatment
favourably impacts vascular event rates in both those
Figure 1 (A) Cardiovascular disease (CVD) mortality and (B)
all-cause mortality per 1000 person years for subjects without
type 2 diabetes (not T2D) and with type 2 diabetes (T2D)
according to statin use and prevalent coronary heart disease
(CHD). Rates have been adjusted to age 75, sex and the mean
levels of cardiovascular risk factors (cholesterol, high-density-
lipoprotein cholesterol, systolic blood pressure, BMI,
triglycerides, hypertensive medication and current smoking)
within each cohort. Follow-up was through 2009 (a median
period of 5.3 years) for the Age, Gene/Environment
Susceptibility-Reykjavik Study. The vertical lines represent the
mortality of all without diabetes (not T2D, N¼4513).
Table 2 Prevalence of type 2 diabetes (T2D) and glucose-lowering treatment in the Age, Gene/Environment Susceptibility-
Reykjavik Study, 2002e2006
AGES-Reykjavik Study Men Women Men and women Percentage of total T2D
Total T2D at baseline, % (n) 16.3 (358) 9.5 (281) 12.4 (639) 100
Diagnosed at study entry, % (n) 5.1 (113) 2.8 (84) 3.8 (197) 31
With prevalent T2D at study entry, % (n) 11.2 (245) 6.7 (197) 8.6 (442) 69
Mean T2D duration, years (6SD) 10.7 (610.0)
Glucose-lowering treatment in prevalent T2D
On special diet only, % (n) 23.3 (57) 34.5 (68)
On diabetic medication, % (n) 76.7 (188) 65.5 (129)
Using one drug, % (n) 43.7 (107) 40.1 (79)
Using two drugs, % (n) 25.7 (63) 19.8 (39)
Using three drugs, % (n) 6.9 (17) 4.6 (9)
Using four drugs, % (n) 0.4 (1) 1.0 (2)
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Statins and mortality in T2Dwith and without diabetes. In the Heart Protection
Study,
2 for example, it was concluded that 40 mg of
simvastatin daily would probably reduce the rate of ﬁrst
major vascular event by about a third. Similarly a 2-year
treatment period with atorvastatin in type 2 diabetes in
the Collaborative Atorvastatin Diabetes Study reduced
the death rate by 27%, prompting an early termination
of the trial.
16 The authors concluded that lipid-lowering
treatment should at least receive the same attention as
glycaemic and blood-pressure control in patients with
type 2 diabetes without a history of cardiovascular
disease, which is in harmony with current clinical
guidelines. Aggressive multifactorial treatment of high-
risk individuals with type 2 diabetes has been shown to
be important,
9 and may also be appropriate for persons
diagnosed above the age of 70. Recent results from
several large studies
17 18 have, however, indicated that
caution may be needed as regards aggressive glucose-
lowering treatment in those with a long-established
coronary heart disease and diabetes of long duration. In
our study, statin use at baseline, but not use of glucose-
lowering medication, is associated with the marked
reduction in cardiovascular and total mortality, reducing
mortality in those with diabetes to a level similar to those
without diabetes.
Statin medication under the rigours of controlled
study conditions in selected individuals has thus been
shown to be helpful.
2 45The novelty of our study is that
statin medication also is very likely to be important in
older persons in the community, persons who may or
may not ﬁt the stringent criteria of normality imposed
for inclusion into randomised clinical trials.
Recently, a large meta-analysis
1 demonstrated that the
increased cardiovascular mortality seen in type 2 dia-
betes is not explained by conventional cardiovascular
risk factors. This suggests that the effect of the statins on
cardiovascular mortality seen in our population-based
cohort may reach beyond the statins’ effect on choles-
terol levels, possibly by reducing the damaging effect of
inﬂammatory agents.
19 20 Inﬂammation as measured by
CRP, however, does not appear to be the explanation in
our study, as adjusting for CRP in the risk models did not
attenuate the RR, although those on statins had a mark-
edly lower CRP. This warrants further study.
The prevalence of diabetes in Iceland is changing in the
same fashion as in other western societies.
21 Furthermore,
the Icelandic population is similar to other western
populations with respect to cardiovascular morbidity and
mortality,
22 and our results are therefore applicable to
other Caucasian populations. Thus, considerable addi-
tional beneﬁt can be expected by adhering to the current
guidelines on statin use in treating individuals with dia-
betes, also in the older age-groups.
In summary, we have estimated the risk of death from
cardiovascular disease and from all causes in a popula-
tion-based cohort of older persons with type 2 diabetes.
Table 3 HRs for the RR of cardiovascular disease (CVD) mortality and all-cause mortality in people with type 2 diabetes (T2D)
compared with all non-diabetics according to prevalent coronary heart disease (chd) and statin use* in the AGES-Reykjavik
Study, 2002e2006
Adjusted for age and sex
Adjusted for age, sex, and
CVD risk factorsy
Adjusted for age, sex, CVD
risk factorsy and C-reactive
protein
HR (95% CI) HR (95% CI) HR (95% CI)
Death from CVD
All T2D 1.71 (1.35 to 2.17) 1.48 (1.15 to 1.90) 1.45 (1.13 to 1.86)
According to CHD and statin use
T2D with CHD not on
statins
4.71 (2.93 to 7.58) 3.33 (2.02 to 5.50) 3.20 (1.94 to 5.29)
T2D with CHD on statins 1.92 (1.08 to 3.43) 1.51 (0.83 to 2.75) 1.55 (0.85 to 2.82)
T2D without CHD and not
on statins
1.53 (1.14 to 2.05) 1.40 (1.03 to 1.89) 1.34 (0.99 to 1.82)
T2D without CHD and on
statins
0.83 (0.37 to 1.85) 0.71 (0.31 to 1.62) 0.75 (0.33 to 1.69)
Death from all causes
All T2D 1.44 (1.22 to 1.69) 1.35 (1.14 to 1.61) 1.32 (1.11 to 1.57)
According to CHD and statin use
T2D with CHD not on
statins
3.48 (2.43 to 4.99) 2.88 (1.98 to 4.18) 2.72 (1.87 to 3.95)
T2D with CHD on statins 1.61 (1.10 to 2.37) 1.34 (0.90 to 1.99) 1.37 (0.92 to 2.04)
T2D without CHD not on
statins
1.34 (1.09 to 1.64) 1.34 (1.08 to 1.64) 1.27 (1.03 to 1.57)
T2D without CHD on
statins
0.77 (0.46 to 1.28) 0.70 (0.42 to 1.17) 0.73 (0.44 to 1.23)
*Individuals on statin medication are identiﬁed as on statins; those not on statin medication as not on statins.
yCVD risk factors: cholesterol, high-density-lipoprotein cholesterol, systolic blood pressure, BMI, triglycerides, hypertensive medication and
current smoking.
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S t a t i n sa n dm o r t a l i t yi nT 2 DThe main ﬁnding is that statin use, irrespective of
glucose-lowering and antihypertensive medication,
eliminates the difference in the mortality of older
persons with type 2 diabetes, compared with those
without diabetes. Our study suggests that treatment with
statins is paramount in the multifaceted management of
type 2 diabetes. Strict adherence to the current guide-
lines is therefore of key importance for older persons
with diabetes, regardless of the presence or absence of
cardiovascular disease or the level of glucose or blood
pressure control.
Our results urgently call for other population-based
studies with comparable information to conﬁrm the
effect of statin use on mortality in individuals with type 2
diabetes.
Author afﬁliations:
1Icelandic Heart Association Research Institute, Kopavogur, Iceland
2Center of Public Health Sciences, University of Iceland, Reykjavik, Iceland
3Faculty of Medicine, University of Iceland, Reykjavik, Iceland
4Department of Endocrinology and Metabolism, Landspitali University
Hospital, Reykjavik, Iceland
5Laboratory of Epidemiology, Demography, and Biometry, Intramural
Research Program, National Institute on Ageing, Bethesda, Maryland, USA
Funding This study has been funded by NIH contract N01-AG-1-2100, the NIA
Intramural Research Program, Hjartavernd (the Icelandic Heart Association),
and Althingi (the Icelandic parliament). The study is approved by the Icelandic
National Bioethics Committee, VSN: 00-063. The researchers are indebted to
the participants for their willingness to participate in the study.
Competing interests None.
Patient consent Obtained.
Contributors VG had access to all the data and takes full responsibility for the
content of this paper. Drafting of the manuscript: EO, TA, RB and VG.
Statistical analysis: EO and TA. Data collection and preparation: EO, TA, VG,
BT, GE, GS, LJL and TBH. All authors contributed to the interpretation of the
results, read and commented on the manuscript, and approved the ﬁnal
version.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data available.
REFERENCES
1. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood
glucose concentration, and risk of vascular disease: a collaborative
meta-analysis of 102 prospective studies. Lancet 2010;375:2215e22.
2. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection
Study of cholesterol-lowering with simvastatin in 5963 people with
diabetes: a randomised placebo-controlled trial. Lancet
2003;361:2005e16.
3. Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL
cholesterol substantially below currently recommended levels in
patients with coronary heart disease and diabetes: the Treating to
New Targets (TNT) study. Diabetes Care 2006;29:1220e6.
4. Kearney PM, Blackwell L, Collins R, et al. Efﬁcacy of cholesterol-
lowering therapy in 18,686 people with diabetes in 14 randomised
trials of statins: a meta-analysis. Lancet 2008;371:117e25.
5. Brugts JJ, Yetgin T, Hoeks SE, et al. The beneﬁts of statins in people
without established cardiovascular disease but with cardiovascular
risk factors: meta-analysis of randomised controlled trials. BMJ
2009;338:b2376.
6. Gulliford MC, Charlton J. Is relative mortality of type 2 diabetes
mellitus decreasing? Am J Epidemiol 2009;169:455e61.
7. Dale AC, Vatten LJ, Nilsen TI, et al. Secular decline in mortality from
coronary heart disease in adults with diabetes mellitus: cohort study.
BMJ 2008;337:a236.
8. Barnett KN, McMurdo ME, Ogston SA, et al. Mortality in people
diagnosed with type 2 diabetes at an older age: a systematic review.
Age Ageing 2006;35:463e8.
9. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of
a multifactorial intervention on mortality in type 2 diabetes. N Engl J
Med 2008;358:580e91.
10. Charlton J, Latinovic R, Gulliford MC. Explaining the decline in early
mortality in men and women with type 2 diabetes: a population-based
cohort study. Diabetes Care 2008;31:1761e6.
11. Dominguez H, Schramm TK, Norgaard ML, et al. Initiation and
persistence to statin treatment in patients with diabetes receiving
glucose-lowering medications 1997e2006. Open Cardiovasc Med J
2009;3:152e9.
12. Harris TB, Launer LJ, Eiriksdottir G, et al. Age, Gene/Environment
Susceptibility-Reykjavik Study: multidisciplinary applied phenomics.
Am J Epidemiol 2007;165:1076e87.
13. World Health Organization. Expert Committee Deﬁnition dacodmaic.
Report of a WHO consultation, part 1: diagnosis and classiﬁcation of
diabetes mellitus. Geneva: WHO Press, 1999.
14. Warnick GR, Knopp RH, Fitzpatrick V, et al. Estimating low-density
lipoprotein cholesterol by the Friedewald equation is adequate for
classifying patients on the basis of nationally recommended
cutpoints. Clin Chem 1990;36:15e19.
15. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year
risk of fatal cardiovascular disease in Europe: the SCORE project.
Eur Heart J 2003;24:987e1003.
16. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary
prevention of cardiovascular disease with atorvastatin in type 2
diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS):
multicentre randomised placebo-controlled trial. Lancet
2004;364:685e96.
17. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive
glucose lowering in type 2 diabetes. N Engl J Med
2008;358:2545e59.
18. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular
complications in veterans with type 2 diabetes. N Engl J Med
2009;360:129e39.
19. Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular
events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-
Scandinavian Cardiac Outcomes Trialelipid-lowering arm (ASCOT-
LLA). Diabetes Care 2005;28:1151e7.
20. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive
protein and LDL cholesterol and cardiovascular event rates after
initiation of rosuvastatin: a prospective study of the JUPITER trial.
Lancet 2009;373:1175e82.
21. Bergsveinsson J, Aspelund T, Gudnason V, et al. [Prevalence of type
2 diabetes mellitus in Iceland 1967e2002]. Laeknabladid
2007;93:397e402.
22. Aspelund T, Thorgeirsson G, Sigurdsson G, et al. Estimation of 10-
year risk of fatal cardiovascular disease and coronary heart disease in
Iceland with results comparable with those of the Systematic
Coronary Risk Evaluation project. Eur J Cardiovasc Prev Rehabil
2007;14:761e8.
PAGE fraction trail=7
Olafsdottir E, Aspelund T, Sigurdsson G, et al. BMJ Open 2011;1:e000132. doi:10.1136/bmjopen-2011-000132 7
Statins and mortality in T2D